Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.

By M. Studeny, F. Marini, J. Dembinski, C. Zompetta, M. Cabreira-Hansen, B. N. Bekele, R. Champlin, Michael Andreeff. Journal of the National Cancer Institute, 2004

886 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/c705005bbff5da8100f8955f301365d20818e334

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. D. Prockop
2. A. Caplan
3. W. Fibbe
4. M. Mareel
5. M. Kay
6. O. De Wever
7. J. Karp
8. Andrea Augello

In Oncology

1. Pieter Demetter
2. M. Bracke
3. M. Mareel
4. O. De Wever
5. W. Stetler-Stevenson
6. M. Kay
7. D. Prockop
8. A. Caplan

In Orthopedics and Sports Medicine

1. A. Caplan

Citations in the corpus

• Stromal myofibroblasts are drivers of invasive cancer growth (2008, background): “Genetically modified MSC’s carrying the human interferon-b gene and intravenously injected into immunodeficient mice with established xenografted human local tumors and metastasis, resulted in a significant improvement in survival compared with controls.(37)”
• Sarcoma Derived from Cultured Mesenchymal Stem Cells (2007, background): “The beneficial effects of MSCs are being tested clinically in attempts to improve hematopoietic engraftment [9], to treat osteogenesis imperfecta [10], graft-versus-host disease [11], and autoimmune diseases [12–14], and to deliver therapy for malignancies [ 15 , 16].”
• Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. (2009, background): “Thus, these cells are considered to be promising tools for cell-targeted therapies and tissue engineering (2, 3).”
• Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma (2006, background): “Previous studies suggest that systemically infused MSCs have the ability to home to sites of active tumorigenesis (21, 32).”
• Mesenchymal stem cells as trophic mediators (2006, background): “, 1999], and a variety of other connective tissues [Studeny et al., 2004].”
• Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression (2009, background): “In those and subsequent studies, we demonstrated that MSC, administered intravenously, were able to integrate and persist within tumor stroma of pre-established human melanoma, breast cancer and glioma xenografts [11,12,16].”